231 related articles for article (PubMed ID: 33504554)
1. Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry.
Martinez-Morilla S; Villarroel-Espindola F; Wong PF; Toki MI; Aung TN; Pelekanou V; Bourke-Martin B; Schalper KA; Kluger HM; Rimm DL
Clin Cancer Res; 2021 Apr; 27(7):1987-1996. PubMed ID: 33504554
[TBL] [Abstract][Full Text] [Related]
2. High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling.
Toki MI; Merritt CR; Wong PF; Smithy JW; Kluger HM; Syrigos KN; Ong GT; Warren SE; Beechem JM; Rimm DL
Clin Cancer Res; 2019 Sep; 25(18):5503-5512. PubMed ID: 31189645
[TBL] [Abstract][Full Text] [Related]
3. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
4. Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy.
Martinez-Morilla S; Moutafi M; Fernandez AI; Jessel S; Divakar P; Wong PF; Garcia-Milian R; Schalper KA; Kluger HM; Rimm DL
Oncoimmunology; 2023; 12(1):2260618. PubMed ID: 37781235
[TBL] [Abstract][Full Text] [Related]
5. Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma.
Wong PF; Wei W; Gupta S; Smithy JW; Zelterman D; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Jul; 7(1):194. PubMed ID: 31337426
[TBL] [Abstract][Full Text] [Related]
6. Imaging mass cytometry for high-dimensional tissue profiling in the eye.
Schlecht A; Boneva S; Salie H; Killmer S; Wolf J; Hajdu RI; Auw-Haedrich C; Agostini H; Reinhard T; Schlunck G; Bengsch B; Lange CA
BMC Ophthalmol; 2021 Sep; 21(1):338. PubMed ID: 34544377
[TBL] [Abstract][Full Text] [Related]
7. uPAR
Porcelli L; Guida M; De Summa S; Di Fonte R; De Risi I; Garofoli M; Caputo M; Negri A; Strippoli S; Serratì S; Azzariti A
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972390
[TBL] [Abstract][Full Text] [Related]
8. Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery.
Giraldo NA; Berry S; Becht E; Ates D; Schenk KM; Engle EL; Green B; Nguyen P; Soni A; Stein JE; Succaria F; Ogurtsova A; Xu H; Gottardo R; Anders RA; Lipson EJ; Danilova L; Baras AS; Taube JM
Cancer Immunol Res; 2021 Nov; 9(11):1262-1269. PubMed ID: 34433588
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.
Wagner NB; Lenders MM; Kühl K; Reinhardt L; André F; Dudda M; Ring N; Ebel C; Stäger R; Zellweger C; Lang R; Paar M; Gussek P; Richtig G; Stürmer SH; Kimeswenger S; Oellinger A; Forschner A; Leiter U; Weide B; Gassenmaier M; Schraag A; Klumpp B; Hoetzenecker W; Berking C; Richtig E; Ziemer M; Mangana J; Terheyden P; Loquai C; Nguyen VA; Gebhardt C; Meier F; Diem S; Cozzio A; Flatz L; Röcken M; Garbe C; Eigentler TK
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986126
[TBL] [Abstract][Full Text] [Related]
10. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.
Bochem J; Zelba H; Spreuer J; Amaral T; Wagner NB; Gaissler A; Pop OT; Thiel K; Yurttas C; Soffel D; Forchhammer S; Sinnberg T; Niessner H; Meier F; Terheyden P; Königsrainer A; Garbe C; Flatz L; Pawelec G; Eigentler TK; Löffler MW; Weide B; Wistuba-Hamprecht K
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933966
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
[TBL] [Abstract][Full Text] [Related]
12. DNA-barcoded signal amplification for imaging mass cytometry enables sensitive and highly multiplexed tissue imaging.
Hosogane T; Casanova R; Bodenmiller B
Nat Methods; 2023 Sep; 20(9):1304-1309. PubMed ID: 37653118
[TBL] [Abstract][Full Text] [Related]
13. An immune risk score with potential implications in prognosis and immunotherapy of metastatic melanoma.
Sheng Y; Tong L; Geyu L
Int Immunopharmacol; 2020 Nov; 88():106921. PubMed ID: 32871477
[TBL] [Abstract][Full Text] [Related]
14. Spatially mapping the immune landscape of melanoma using imaging mass cytometry.
Moldoveanu D; Ramsay L; Lajoie M; Anderson-Trocme L; Lingrand M; Berry D; Perus LJM; Wei Y; Moraes C; Alkallas R; Rajkumar S; Zuo D; Dankner M; Xu EH; Bertos NR; Najafabadi HS; Gravel S; Costantino S; Richer MJ; Lund AW; Del Rincon SV; Spatz A; Miller WH; Jamal R; Lapointe R; Mes-Masson AM; Turcotte S; Petrecca K; Dumitra S; Meguerditchian AN; Richardson K; Tremblay F; Wang B; Chergui M; Guiot MC; Watters K; Stagg J; Quail DF; Mihalcioiu C; Meterissian S; Watson IR
Sci Immunol; 2022 Apr; 7(70):eabi5072. PubMed ID: 35363543
[TBL] [Abstract][Full Text] [Related]
15. High Dimensional Imaging Mass Cytometry Panel to Visualize the Tumor Immune Microenvironment Contexture.
Elaldi R; Hemon P; Petti L; Cosson E; Desrues B; Sudaka A; Poissonnet G; Van Obberghen-Schilling E; Pers JO; Braud VM; Anjuère F; Meghraoui-Kheddar A
Front Immunol; 2021; 12():666233. PubMed ID: 33936105
[TBL] [Abstract][Full Text] [Related]
16. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
17. High-Plex Spatially Resolved RNA and Protein Detection Using Digital Spatial Profiling: A Technology Designed for Immuno-oncology Biomarker Discovery and Translational Research.
Beechem JM
Methods Mol Biol; 2020; 2055():563-583. PubMed ID: 31502169
[TBL] [Abstract][Full Text] [Related]
18. OPTIMAL: An OPTimized Imaging Mass cytometry AnaLysis framework for benchmarking segmentation and data exploration.
Hunter B; Nicorescu I; Foster E; McDonald D; Hulme G; Fuller A; Thomson A; Goldsborough T; Hilkens CMU; Majo J; Milross L; Fisher A; Bankhead P; Wills J; Rees P; Filby A; Merces G
Cytometry A; 2024 Jan; 105(1):36-53. PubMed ID: 37750225
[TBL] [Abstract][Full Text] [Related]
19. Mapping the single cell spatial immune landscapes of the melanoma microenvironment.
Magrill J; Moldoveanu D; Gu J; Lajoie M; Watson IR
Clin Exp Metastasis; 2024 Jan; ():. PubMed ID: 38217840
[TBL] [Abstract][Full Text] [Related]
20. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
